Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Lo

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Open Forum Infectious Diseases|December 10, 2021
Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency VirusEmma M Kileel, Janet Lo, Carlos Malvestutto, et al.
The Journal of Infectious Diseases|April 21, 2020
Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics ApproachChris deFilippi, Mabel Toribio, Lai Ping Wong, et al.
Psychoneuroendocrinology|June 29, 2021
A neurobiological link between transportation noise exposure and metabolic disease in humansMichael T Osborne, Nicki Naddaf, Shady Abohashem, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2023
Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)Emma M Kileel, Carlos D Malvestutto, Janet Lo, et al.
The Journal of Infectious Diseases|October 17, 2020
Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, et al.
The Journal of Infectious Diseases|July 10, 2020
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, et al.
Metabolism: Clinical and Experimental|August 20, 2013
Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitusGeoffrey A Walford, Jaclyn Davis, A Sofia Warner, et al.
Neurosurgery|June 20, 2019
Letter: When Less is More: Dexamethasone Dosing for Brain TumorsMary Jane Lim-Fat, Wenya Linda Bi, Janet Lo, et al.
The Lancet. HIV|March 30, 2026
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVEEmma M Kileel, Carlos D Malvestutto, Markella V Zanni, et al.
Plos One|March 27, 2015
The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetesGeoffrey A Walford, Natalia Colomo, Jennifer N Todd, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Open Forum Infectious Diseases|December 10, 2021
Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency VirusEmma M Kileel, Janet Lo, Carlos Malvestutto, et al.
The Journal of Infectious Diseases|April 21, 2020
Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics ApproachChris deFilippi, Mabel Toribio, Lai Ping Wong, et al.
Psychoneuroendocrinology|June 29, 2021
A neurobiological link between transportation noise exposure and metabolic disease in humansMichael T Osborne, Nicki Naddaf, Shady Abohashem, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2023
Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)Emma M Kileel, Carlos D Malvestutto, Janet Lo, et al.
The Journal of Infectious Diseases|October 17, 2020
Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, et al.
The Journal of Infectious Diseases|July 10, 2020
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, et al.
Metabolism: Clinical and Experimental|August 20, 2013
Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitusGeoffrey A Walford, Jaclyn Davis, A Sofia Warner, et al.
Neurosurgery|June 20, 2019
Letter: When Less is More: Dexamethasone Dosing for Brain TumorsMary Jane Lim-Fat, Wenya Linda Bi, Janet Lo, et al.
The Lancet. HIV|March 30, 2026
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVEEmma M Kileel, Carlos D Malvestutto, Markella V Zanni, et al.
Plos One|March 27, 2015
The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetesGeoffrey A Walford, Natalia Colomo, Jennifer N Todd, et al.
Pageof 9